Table 1.
Patient characteristics
| Characteristic | IV IL-15 | SC IL-15 | P |
|---|---|---|---|
| N | 26 | 16 | |
| Time period | 2011-2015 | 2015-2016 | |
| Median age (range), y | 52 (22-68) | 63 (20-71) | .05 |
| Male sex | 14 (54) | 12 (75) | NS |
| KPS <80 | 2 (8) | 2 (13) | NS |
| Blasts by morphology | NS | ||
| Mean (SD) | 35.5 (29.5) | 25.1 (24.8) | NS |
| ELN risk group | NS | ||
| Favorable | 1 | 2 (13) | |
| Intermediate | 14 (50) | 4 (25) | |
| Adverse | 10 (50) | 10 (63) | |
| Molecular mutations | |||
| FLT3-ITD+ | 7 (27) | 2 (13) | NS |
| NPM1+ | 1 (4) | 1 (6) | NS |
| AML subtype | <.01 | ||
| De novo | 21 (81) | 5 (31) | |
| Secondary AML | 4 (15) | 9 (56) | |
| t-AML | 1 (4) | 2 (13) | |
| Mean no. of prior therapies (SD) | 3.0 (1.3) | 2.3 (0.6) | NS |
| No. of patients receiving prior hematopoietic cell transplantation | 3 (12) | 3 (19) | NS |
| Seropositive CMV | |||
| Recipient | 13 (50) | 9 (56) | NS |
| Donor | 9 (35) | 4 (25) | NS |
| KIR mismatch | NS | ||
| Unknown | 0 | 1 | |
| No | 20 (78) | 9 (60) | |
| Yes | 6 (22) | 6 (40) |
All data are n (%), except as noted.
ELN, European LeukemiaNet; ITD, internal tandem duplication; KIR, killer cell immunoglobulin-like receptor; KPS, Karnofsky performance status; NS, not significant; SD, standard deviation; t-AML, therapy-related AML.